Mirati Therapeutics Inc (MRTX)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | David D. Meek |
| Employees: | 590 |
| Web site: | mirati.com |
|
3545 CRAY COURT, SAN DIEGO, CA, 92121
858-332-3410
| |
• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers. Sitravatinib, an investigational spectrum-selective kinase inhibitor, is in clinical trials for the treatment of NSCL cancer.
Please log in first to see chart